More than 70% of drug candidates worldwide are chiral.  For a chiral API, the production of optically pure enantiomer or diastereomer is imperative since only one of the pair is biologically active.  Crystal Pharmatech utilizes a well developed rationale and strategy for purification of partially resolved mixtures based on ternary phase diagrams.  With this full understanding of the system, an optimized chiral resolution process can be designed to upgrade ee with maximum yield.

A Workflow for ee Upgrade Crystallization Process Development:

Ee Upgrade of A Conglomerate System with the Guidance of Tenrary Phase Diagram:

References:

Enantioenrichment by Crystallization, Y. Wang and A. M. Chen, Org. Process Res. Dev., 2008, 12 (2), pp 282–290